Qiyu Biotechnology, a Shanghai startup located in Zhangjiang Hi-Tech Park, completed a Series A round that raised “tens of millions of RMB” from Jundu Investment and Wosheng Capital. This proceeds are earmarked to support the pre-clinical development of the company’s large molecule candidates. Established in 2017, Qiyu is developing novel candidates to treat difficult cancers, autoimmune diseases and metabolic diseases for China and aboard. The company is a product of Zhangjiang’s Viva International Incubator. Source: China Biotoday
